University Hospitals and Case Western Reserve University School of Medicine to Conduct Smallpox Vaccine Research Study
CLEVELAND -- University Hospitals Case Medical Center (UHCMC) and Case Western Reserve University School of Medicine are part of a nationwide research study to determine the safety and effectiveness of a new smallpox vaccine geared toward adults ages 18 to 34 who have never been vaccinated against the disease. The study is the first of its type in northeast Ohio.
The current FDA-approved vaccine, Dryvax®, is not recommended for use on everyone because of the potential for serious side effects in certain individuals. For example, the current vaccine cannot be used in immune-compromised individuals, such as patients with HIV or individuals with certain skin conditions such as eczema, says Robert A. Salata, MD, chief of the Division of Infectious Diseases at Case Western Reserve University School of Medicine and UHCMC.
The new vaccine, IMVAMUNE®, is different from Dryvax® in that it contains a more weakened form of the live-virus within the vaccine.
Because the vaccine is weakened, the side effects should be minimized enough to give the vaccine to all individuals, even those whose immune systems are suppressed, says Salata. Our hope is that the new vaccine will be a safer alternative to the current vaccine.
UHCMC and the School of Medicine will act as a subunit of St. Louis Universitys Center for Vaccine Development, which is one of seven national testing sites known as Vaccine and Treatment Evaluation Units (VTEUs), designated by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
The research study, which is actively recruiting and begins here June 15, will follow 215 volunteers nationwide over a two-year period. Volunteers must be in general good health and must not have previously been vaccinated against smallpox.
Smallpox is a contagious and sometimes fatal infectious disease characterized by raised bumps that appear on the face and body of an infected person. There is no specific treatment for smallpox disease, and the only prevention is vaccination. The World Health Organization declared the disease eradicated in 1980 with the success of a worldwide vaccination program. Routine vaccination against smallpox among the general public was ceased in 1972 because it was no longer necessary for prevention. However, recent threats of bioterrorism after 9/11 have spurred the development of a new safer vaccine that can be given to immune-compromised individuals.
For more information about the study and how to participate, call the Division of Infectious Diseases at (216) 368-2003, or e-mail vaccinecenter@case.edu . Additional information can be found under the vaccine research unit link at www.cwru.id.orgÂ
Source: University Hospitals Case Medical Center
Â
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.
A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings
July 9th 2025Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.
